
Bristol-Myers Squibb Company (BMY) Gains After Deep Q3 Earnings
Bristol-Myers Squibb Company (BMY) gains after a deep Q3 earnings review showing beats on EPS and revenue, stronger growth-brand sales, and raised revenue guidance. The analysis also weighs margin pressure, lower EPS guidance, and the ongoing shift away from legacy products.





